Cardiac valvular disease
Conditions
Interventions
experimental group:Dexmedetomidine Intravenous injection
placebo group:Intravenous injection
Sponsors
Fujian Medical University Union Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Aged >=18 years; American Standards Association(ASA) grade II- III, normal renal function, cardiac function I - III level, line elective general anesthesia surgery under extracorporeal circulation in valve surgery or forming.
Exclusion criteria
Exclusion criteria: (1) BMI 35 kg / ?; (2) Preoperative pulmonary infection, liver and kidney dysfunction, and previous history of open-heart surgery; (3) Patients with missing preoperative or postoperative data, such as serum creatinine; (4) Preoperative nephrotoxic drugs, such as aminoglycoside antibiotics, NASAI drugs and contrast agents, were used within 48 hours; (5) Participate in clinical trials of other drugs in the same period; (6) Infectious or infectious diseases, COVID-19, hepatitis B and syphilis; (7) Allergic to drugs such as dexmedetomidine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum creatinine and urea l;Serum inflammatory markers;the outcome of arterial blood gas analysis;Postoperative recovery;hemodynamics; | — |
Secondary
| Measure | Time frame |
|---|---|
| cardiac function;liver function; | — |
Countries
China
Contacts
Public ContactLiping Yang
Fujian Medical University Union Hospital
Outcome results
None listed